Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

Yosra Aljawai, Ah-Reum Jeong, Muthalagu Ramanathan, Gunjan Shah, Hyung Suh, John Hiemenz, Jonathan Licht, William Clark, Luke Akard, Ann Woolfrey, Devki Sukhtankar, Pina Cardarelli, Nina Caculitan, Jack Khouri

Blood (2025) 146 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2025-1050

Published: 2025

Journal Articles

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Sarah Larson, Umar Farooq, Tahir Latif, Felix Mensah, Bradley Hunter, Stefan Ciurea, Nebu Koshy, Locke Bryan, Boyu Hu, William Clark, Hassaan Yasin, Yeonhee Kim, Greg Kaufman, Akil Merchant

Blood (2025) 146 (Supplement 1): 668.

https://doi.org/10.1182/blood-2025-668

Published: 2025

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

The impact of cytokine release syndrome on survival following allogeneic stem cell transplantation with post transplantation cyclophosphamide: Insights from real-world data

Carolina Velez-Mejia, Esteban Toro Velez, Brian Cassel, John McCarty, Sneha Purvey, William Clark

Blood (2025) 146 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2025-4212

Published: 2025

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Blood (2021) 138 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2021-149313

Published: 2021

Journal Articles

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-143079

Published: 2020

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange

Gail Rock, PhD MD, Steven Weger, MD, Hana Abouhadjar, MD, David Barth, MD FRCPC, William Clark, MD, Paul R. Yenson, MD FRCPC, Stephen Ronan Foley, MD FRCPC

Blood (2015) 126 (23): 2261.

https://doi.org/10.1182/blood.V126.23.2261.2261

Published: 2015

Journal Articles

Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia

Anne-Louise Latif, MBChB, John J Cole, Joana Monteiro Campos, William Clark, Lynn McGarry, PhD, Claire Brock, Ashley Newcombe, Karen Keeshan, PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Peter D Adams, PhD

Blood (2015) 126 (23): 674.

https://doi.org/10.1182/blood.V126.23.674.674

Published: 2015

Journal Articles

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Amir A Toor, MD, Roy T Sabo, PhD, Harold M Chung, MD, Catherine H Roberts, PhD, Rose H Manjili, BS, Shiyu Song, MD, PhD, David C. Williams, Jr., MD, PhD, William Clark, MD, Masoud H Manjili, DVM, PhD, John M McCarty, MD

Blood (2011) 118 (21): 3043.

https://doi.org/10.1182/blood.V118.21.3043.3043

Published: 2011

Journal Articles

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Amir A Toor, MD, Kyle Payne, BS, Harold M Chung, MD, Catherine H Roberts, PhD, Roy T Sabo, PhD, Maciej Kmieciak, PhD, William Clark, MD, Christy McLaughlin, BS, Angela Buskey, RN, Jennifer Anderson, RN, Rose H Manjili, BS, Susan D. Roseff, MD, John M McCarty, MD, Masoud H Manjili, DVM, PhD

Blood (2011) 118 (21): 2926.

https://doi.org/10.1182/blood.V118.21.2926.2926

Published: 2011

Journal Articles

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

William Clark, MD, Dana Crawford, Ph.D, Brian Engelhardt, MD, MS, Kristin D. Brown, Fan Kang-Hsien, PhD, Heidi Chen, PhD, Bipin N. Savani, MD, Friedrich Schuening, MD, John P. Greer, MD, Adetola A. Kassim, MD, MS, Madan Jagasia, MD, MS

Blood (2010) 116 (21): 215.

https://doi.org/10.1182/blood.V116.21.215.215

Published: 2010

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.

Gail A. Rock, Phd, MD, FRCPC, David Anderson, MD, Barrett Benny, MD, David Barth, MD, William Clark, MD, Ronan Foley, MD, David Sutton, MD, Pierre Leblond, MD

Blood (2007) 110 (11): 2895.

https://doi.org/10.1182/blood.V110.11.2895.2895

Published: 2007

Journal Articles

Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.

Gail Rock, PhD, MD, FRCP, David Anderson, Barrett Benny, William Clark, Pierre Leblond, David Sutton, Marion Sternbach, George Wells, Members of the Canadian Apheresis Group, Canadian Association of Apheresis Nurses

Blood (2005) 106 (11): 3989.

https://doi.org/10.1182/blood.V106.11.3989.3989

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

The impact of cytokine release syndrome on survival following allogeneic stem cell transplantation with post transplantation cyclophosphamide: Insights from real-world data

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange

Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.

Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only